Clinical Evaluation of Multifocal Intraocular Lens: OPTIVIS.TM (Evolución clínica de Lente Intraocular Multifocal: OPTIVIS.TM)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cataract Senile
- Sponsor
- Parc de Salut Mar
- Enrollment
- 32
- Primary Endpoint
- Visual function
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
This study evaluated visual outcome after cataract surgery with bilateral implantation of either a diffractive - refractive (hybrid) multifocal intraocular lens (MFIOL) or monofocal intraocular lens (IOL) as a control grup.
Detailed Description
PURPOSE: To present the outcomes of hybrid multifocal and monofocal intraocular lenses (IOL) SETTING: Parc de Salut Mar, Universidad Pompeu-Fabra - Autónoma, Barcelona, Spain. DESIGN: Prospective clinical trial. METHODS: Consecutive patients with bilateral cataract were included. Phacoemulsification with randomized implantation of either a monofocal IOL (AR40e, AMO-Abbot 30 Laboratories Inc. Abbot Park, Illinois, USA) or multifocal IOL (OptiVis™, Aaren Scientific, Inc, Ontario, CA, USA) was performed by the same surgeon and under the same conditions. Over a 3-month follow-up, the main outcome measures were uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), uncorrected intermediate visual acuity at 60 cm (UIVA), distance-corrected intermediate visual acuity (DCIVA), uncorrected near visual acuity at 33 cm (UNVA), distance-corrected near visual acuity (DCNVA), spherical equivalent (SE), contrast sensitivity (CS), presence of dysphotopsia, use of spectacles and patient satisfaction with the test VF-14 (Visual Function Index) .
Investigators
ANNA MARTÍNEZ PALMER
Head of Ophthalmology Department
Parc de Salut Mar
Eligibility Criteria
Inclusion Criteria
- •senile cataract with Snellen visual acuity ≤ 0.5,
- •motivation for spectacle independence for near vision (as the study was conducted in Spanish public health care system, entering study was the only option to get multifocal lens, as they are not provided by public health care, and the patients were conscious of the possibility of randomization to monofocal group.)
Exclusion Criteria
- •corneal astigmatism ≥ 1.10 diopters (D) and irregular astigmatism,
- •axial length \< 21.5 or ≥ 25 mm,
- •pupillary diameter in mesopic conditions in distance vision ≤ 2.5 mm and ≥ 6 mm,
- •ocular pathology that could affect the visual function and/or intraocular lens centering and intraoperative or postoperative complications.
- •highly demanding patients and those whose profession could be affected by a multifocal design (professional drivers, jewelers etc.) were also excluded (as in the Spanish public health care system secondary procedures needed to satisfy patients' expectation, such as LRI´s, LASIK, PRK´s, are not available).
Outcomes
Primary Outcomes
Visual function
Time Frame: The last follow-up visit (3 months after the surgery)
Changes in visual acuity in logMAR: uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA) at 6 m, uncorrected intermediate visual acuity (UIVA), distance-corrected intermediate visual acuity (DCIVA) at 60 cm (in the OptiVis group only, as they were supposed to provide intermediate distance vision in contrary to monofocal lenses), uncorrected near visual acuity (UNVA) and distance-corrected near visual acuity (DCNVA) at 33 cm. All measured using Snellen acuity charts under photopic conditions.
Secondary Outcomes
- Contrast sensitivity (CS)(The last follow-up visit (3 months after the surgery))
- Refractive Outcomes(The last follow-up visit (3 months after the surgery))
- Spectacle dependence(The last follow-up visit (3 months after the surgery))
- Presence of dysphotopsia(The last follow-up visit (3 months after the surgery))
- Patient satisfaction(The last follow-up visit (3 months after the surgery))